Detailed Narrative
Q1 FY26 Financial Performance Overview
Indoco Remedies reported consolidated net revenues of ₹4,291 million for Q1 FY26, marking an 11.77% sequential growth from ₹3,839 million in Q4 FY25. However, standalone net revenues saw a 2.64% YoY decline to ₹3,838 million. Consolidated EBITDA margin improved significantly to 4.1% from a negative figure in the previous quarter, while standalone EBITDA margin stood at 3.9%.
Regulatory and Operational Progress
The company announced that European authorities have approved its Goa Plant-2 for sterile product supply, a positive step in its remediation efforts. For the US FDA warning letter on Goa Plant-2, management expects to complete most remediation by August 2025 and plans to invite the FDA for an audit from September. The master manufacturing program's Phase-1 rollout has seen 3 out of 4 plants become fully operational, with all plants expected to be fully functional by Q3 FY26, aiming for improved efficiency.
Domestic and International Business Dynamics
Domestic formulation business grew by 1.3% YoY to ₹2,028 million. While optically flat, management highlighted a 10% growth for Indoco Remedies in the covered market according to IQVIA, outperforming the industry's 8% growth. The OTC business demonstrated robust growth of over 46% QoQ. International formulation business, however, declined by 11.46% YoY to ₹1,393 million, primarily due to a 41.7% drop in US business revenue to ₹283 million. Emerging markets showed strong growth of 48.66% YoY to ₹443 million.
Capital Allocation and Debt Management
As of June 30, 2025, the company's total consolidated debt stood at ₹950 crores, comprising ₹350 crores short-term and ₹600 crores long-term. Indoco Remedies repaid ₹21 crores in Q1 FY26 and plans to repay an additional ₹68 crores over the next nine months. Incremental CAPEX for FY26 is projected to be around ₹50 crores, primarily for ongoing projects at Goa Plant-2 and the API site for Warren Remedies. Management confirmed plans to infuse capital into Warren Remedies, which currently has a negative net worth of ₹52 crores.
Cost Control and Profitability Outlook
Management is focused on cost containment across all manufacturing sites and sales functions to improve profitability. The goal is to return to historical EBITDA levels of 11-13% with a commitment to quarter-on-quarter improvement. Remediation costs are expected to continue at approximately ₹4 crores per quarter. R&D expenses are targeted to be maintained at 5%-5.5% of revenue, with plans to file 4-5 products this year. The Warren Remedies OTC business achieved EBITDA breakeven in Q1 FY26.